Claims for Patent: 7,935,799

Summary for Patent: 7,935,799

Title:	Methods of treating diarrhea caused by small intestinal bacterial overgrowth
Abstract:	Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis of any of those diagnostic categories. Also disclosed is a method of treating these disorders, and other disorders caused by SIBO, that involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of anti-microbial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. The method improves symptoms, including hyperalgesia related to SIBO and disorders caused by SIBO. Also disclosed is a kit for the diagnosis or treatment of irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, or Crohn's disease.
Inventor(s):	Lin; Henry C. (Albuquerque, NM), Pimentel; Mark (Los Angeles, CA)
Assignee:	Cedars-Sinai Medical Center (Los Angeles, CA)
Application Number:	12/550,303
Patent Claims:	1. A method of treating relapsing diarrhea in a subject who has small intestinal bacterial overgrowth, comprising: providing a composition comprising rifaximin; and administering the composition to the subject who has small intestinal bacterial overgrowth in an amount sufficient to at least partially eradicate small intestinal bacterial overgrowth in the subject and treat the relapsing diarrhea. 2. The method of claim 1, wherein the rifaximin is administered orally. 3. The method of claim 1, wherein the composition comprises a unitized amount of rifaximin. 4. The method of claim 1, wherein the rifaximin is dehydrated rifaximin. 5. The method of claim 1, where in the rifaximin is lyophilized rifaximin. 6. The method of claim 1, wherein the administering results in complete eradication of the small intestinal bacterial overgrowth. 7. The method of claim 1, wherein the administering results in greater than 90% improvement in diarrhea. 8. A method of treating diarrhea in a subject who has small intestinal bacterial overgrowth but does not have any other predisposing factor for diarrhea, comprising: providing a composition comprising rifaximin; and administering the composition to the subject who has small intestinal bacterial overgrowth, but does not have any other predisposing factor for diarrhea in an amount sufficient to at least partially eradicate small intestinal bacterial overgrowth in the subject and treat the diarrhea. 9. The method of claim 8, wherein the rifaximin is administered orally. 10. The method of claim 8, wherein the composition comprises a unitized amount of rifaximin. 11. The method of claim 8, wherein the rifaximin is dehydrated rifaximin. 12. The method of claim 8, where in the rifaximin is lyophilized rifaximin. 13. The method of claim 8, wherein the administering results in complete eradication of the small intestinal bacterial overgrowth. 14. The method of claim 8, wherein the administering results in greater than 90% improvement in diarrhea. 15. A method of treating diarrhea in a subject who has small intestinal bacterial overgrowth, comprising: providing a composition comprising rifaximin; and administering the composition to the subject who has small intestinal bacterial overgrowth in an amount sufficient to at least partially eradicate small intestinal bacterial overgrowth in the subject and treat the diarrhea. 16. The method of claim 15, wherein the rifaximin is administered orally. 17. The method of claim 15, wherein the composition comprises a unitized amount of rifaximin. 18. The method of claim 15, wherein the rifaximin is dehydrated rifaximin. 19. The method of claim 15, where in the rifaximin is lyophilized rifaximin. 20. The method of claim 15, wherein the administering results in complete eradication of the small intestinal bacterial overgrowth. 21. The method of claim 15, wherein the administering results in greater than 90% improvement in diarrhea.